


Preselw  
09/966109

=> d 13 que stat  
L1 STR



Page 1-A

C  
1

Page 1-B

NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE  
L3 0 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 7 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

=> => d 16 que stat;fil medl,hcapl,biosis,embase;s hopmann, c?/au or hopmann  
c?/au;kurz, m?/au or kurz m?/au  
L4 STR



Searched by: Mary Hale 571-272-2507 REM 1D86

Page 1-A

C  
1

Page 1-B

NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE  
L6 0 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 6 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	314.62	314.83

FILE 'MEDLINE' ENTERED AT 10:09:59 ON 22 JUN 2004

FILE 'HCAPLUS' ENTERED AT 10:09:59 ON 22 JUN 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:09:59 ON 22 JUN 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 10:09:59 ON 22 JUN 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

L7	2 FILE MEDLINE
L8	23 FILE HCAPLUS
L9	10 FILE BIOSIS
L10	5 FILE EMBASE

TOTAL FOR ALL FILES  
L11 40 HOPMANN, C?/AU OR HOPMANN C?/AU

KURZ, IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s kurz, m?/au or kurz m?/au  
L12 144 FILE MEDLINE  
L13 279 FILE HCAPLUS  
L14 196 FILE BIOSIS  
L15 139 FILE EMBASE

Searched by: Mary Hale 571-272-2507 REM 1D86

TOTAL FOR ALL FILES

L16 758 KURZ, M?/AU OR KURZ M?/AU

=> s l16 and l11

L17 0 FILE MEDLINE

L18 5 FILE HCAPLUS

L19 4 FILE BIOSIS

L20 1 FILE EMBASE

TOTAL FOR ALL FILES

L21 10 L16 AND L11

=> dup rem l21

PROCESSING COMPLETED FOR L21

L22 8 DUP REM L21 (2 DUPLICATES REMOVED)

=> d cbib abs 1-8

L22 ANSWER 1 OF 8 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2003:584838 Document No.: PREV200300586920. Amycomycin, a process for its production and its use as a pharmaceutical. **Hopmann, Cordula**

[Inventor, Reprint Author]; **Kurz, Michael** [Inventor]; Decker, Heinrich [Inventor]; Le Beller, Dominique [Inventor]; Aszodi, Jozsef [Inventor]. Frankfurt am Main, Germany. ASSIGNEE: Aventis Pharma Deutschland GmbH, Frankfurt am Main, Germany. Patent Info.: US 6642391 November 04, 2003. Official Gazette of the United States Patent and Trademark Office Patents, (Nov 4 2003) Vol. 1276, No. 1. <http://www.uspto.gov/web/menu/patdata.html>. e-file. ISSN: 0098-1133 (ISSN print). Language: English.

AB A compound named Amycomycin of the formula: ##STR1## is described, as well as its pharmaceutically acceptable salts and derivatives, in all their stereoisomeric and tautomeric forms. The compound is obtained by growing the microorganism Amycolatopsis species ST101170 (DSM 12216) and is useful as a pharmaceutical, particularly as an antibiotic.

L22 ANSWER 2 OF 8 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2003:378412 Document No.: PREV200300378412. Percyquinnin, a process for its production and its use as a pharmaceutical. **Hopmann, Cordula**

[Inventor, Reprint Author]; **Kurz, Michael** [Inventor]; Mueller, Guenter [Inventor]; Toti, Luigi [Inventor]. Frankfurt am Main, Germany. ASSIGNEE: Aventis Pharma Deutschland GmbH, Frankfurt am Main, Germany. Patent Info.: US 6596518 July 22, 2003. Official Gazette of the United States Patent and Trademark Office Patents, (July 22 2003) Vol. 1272, No. 4. <http://www.uspto.gov/web/menu/patdata.html>. e-file. ISSN: 0098-1133 (ISSN print). Language: English.

AB The present invention relates to a compound named Percyquinnin that is obtainable by cultivating a basidiomycetes Stereum complicatum (DSM 13303), and to its pharmaceutically acceptable salts. The present invention further relates to a process for the production of Percyquinnin and to the use of Percyquinnin and its pharmaceutically acceptable salts as pharmaceuticals, in particular to their use as inhibitors of lipase.

L22 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

2002:253013 Document No. 136:278226 Citrullimycines, a process for their production and their use as pharmaceuticals. **Hopmann, Cordula; Kurz, Michael**; Broenstrup, Mark; Wink, Joachim (Aventis Pharma Deutschland G.m.b.H., Germany). Eur. Pat. Appl. EP 1193249 A1 20020403, 16 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (English). CODEN: EPXXDW. APPLICATION: EP 2000-121566 20001002.

AB The present invention relates to a compds. named citrullimycines which are obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309), and

to their pharmaceutically acceptable salts. The present invention further relates to a process for the production of the citrullimycines, to the microorganism *Streptomyces* sp., ST 101396 (DSM 13309), to the use of the citrullimycines and their pharmaceutically acceptable salts as a pharmaceutical, in particular to their use as inhibitors of the neurotensin receptor, and to pharmaceutical compns. comprising Citrullimycines or a pharmaceutically acceptable salt thereof.

L22 ANSWER 4 OF 8 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN 2002:338518 Document No.: PREV200200338518. Vancoresmycin, a process for its production and its use as a pharmaceutical. Ramakrishna, Nirogi Venkata Satya [Inventor, Reprint author]; Bhat, Ravi Gajanan [Inventor]; Sreekumar, Eyyammadichiyil Sankaranarayanan [Inventor]; Vijayakumar, Erra Koteswara Satya [Inventor]; Naker, Shantilal Dayaram [Inventor]; Oak, Uttara Vinayak [Inventor]; Tanpure, Rajendra Prakash [Inventor]; **Hopmann, Cordula** [Inventor]; **Kurz, Michael** [Inventor]; Wink, Joachim [Inventor]; Seibert, Gerhard [Inventor]; Le Beller, Dominique [Inventor]; Aszodi, Jozsef [Inventor]. Mumbai, India. ASSIGNEE: Aventis Pharma Deutschland GmbH, Frankfurt am Main, Germany. Patent Info.: US 6387943 May 14, 2002. Official Gazette of the United States Patent and Trademark Office Patents, (May 14, 2002) Vol. 1258, No. 2. <http://www.uspto.gov/web/menu/patdata.html>. e-file. CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB The present invention relates to a compound named Vancoresmycin which is obtainable by cultivation of the microorganism HIL-006734 (DSM 12216), and to its pharmaceutically acceptable salts. The present invention further relates to a process for the production of Vancoresmycin, to the microorganism HIL-006734 (DSM 12216), to the use of Vancoresmycin and its pharmaceutically acceptable salts as pharmaceuticals, and in particular to their use as antibiotics, and to pharmaceutical compositions comprising Vancoresmycin or a pharmaceutically acceptable salt thereof.

L22 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1 2002:1312 Document No. 136:275792 Isolation and structure elucidation of vancoresmycin-a new antibiotic from *Amycolatopsis* sp. ST 101170. **Hopmann, Cordula; Kurz, Michael**; Bronstrup, Mark; Wink, Joachim; LeBeller, Dominique (LG Natural Products Research, Aventis Pharma Deutschland GmbH, Frankfurt a. M., 65926, Germany). Tetrahedron Letters, 43(3), 435-438 (English) 2002. CODEN: TELEAY. ISSN: 0040-4039. Publisher: Elsevier Science Ltd..


GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB A new antibiotic, active against Gram-pos. bacteria, has been isolated from the fermentation broth of the actinomycete *Amycolatopsis* sp. ST 101170. The structure of the compound, named vancoresmycin (I), a tetramic acid derivative with a highly oxygenated long alkyl chain, was elucidated by extensive spectroscopic studies and derivatization.

L22 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN 2001:747164 Document No. 135:287595 Fermentative preparation of lipase-inhibiting percyquinnin using the fungus *Stereum complicatum* ST 001837 (DSM 13303). **Hopmann, Cordula; Kurz, Michael**; Mueller, Guenter; Toti, Luigi (Aventis Pharma Deutschland G.m.b.H., Germany). Eur. Pat. Appl. EP 1142886 A1 20011010, 13 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (English). CODEN: EPXXDW. APPLICATION: EP 2000-107536 20000407.

GI



AB Percyquinnin (I), and its pharmaceutically acceptable salts, which are lipase inhibitors, are fermentatively prepared using the fungus *Stereum complicatum* ST 001837 (DSM 13303).

L22 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

2001:432883 Document No. 135:32809 Amycomycin, a process for its production and its use as a pharmaceutical. **Hopmann, Cordula; Kurz, Michael;** Decker, Heinrich; Le Beller, Dominique; Aszodi, Jozsef (Aventis Pharma Deutschland G.m.b.H., Germany). Eur. Pat. Appl. EP 1106604 A1 20010613, 12 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (English). CODEN: EPXXDW. APPLICATION: EP 1999-124456 19991208.

AB A compound named amycomycin of the formula C<sub>65</sub>H<sub>115</sub>N<sub>018</sub> and its pharmaceutically acceptable salts and derivs., in all their stereoisomeric and tautomeric forms is obtainable by cultivation of the microorganism *Amycolatopsis* sp. ST101170 (DSM 12216) and finds use as a pharmaceutical, particularly as an antibiotic.

L22 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

2000:335584 Document No. 132:346708 Vancoresmycin, a process for its production and its use as a pharmaceutical. Ramakrishna, Nirogi Venkata Satya; Bhat, Ravi Gayanan; Sreekumar, Eyyammadichiyil Sankaranarayanan; Vijayakumar, Erra Koteswara Satya; Naker, Shantilal Dayaram; Oak, Uttara Vinayak; Tanpure, Rajendra Prakash; **Hopmann, Cordula; Kurz, Michael;** Wink, Joachim; Seibert, Gerhard; Le Beller, Dominique; Aszodi, Jozsef (Aventis Pharma Deutschland GmbH, Germany). PCT Int. Appl. WO 2000028064 A1 20000518, 27 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP8415 19991104. PRIORITY: EP 1998-121299 19981109.

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB A compound named Vancoresmycin (I) has been obtained by cultivation of an actinomycete, *Amycolatopsis* HIL-006734 (DSM 12216). A process for the production of I, the isolation and storage of microorganism HIL-00673 (DSM 12216), the extraction and purification of I are reported. I has been extensively characterized and is reported to be a new natural product with the mol.

Searched by: Mary Hale 571-272-2507 REM 1D86

formula C71H126N2O21 and mol. weight 1343.8. The use of I and its pharmaceutically acceptable salts as antibiotics are demonstrated by its effectiveness against microorganisms resistant to methicillin and vancomycin.

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	23.81	338.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.47	-3.47

FILE 'REGISTRY' ENTERED AT 10:10:43 ON 22 JUN 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUN 2004 HIGHEST RN 697224-75-2  
DICTIONARY FILE UPDATES: 21 JUN 2004 HIGHEST RN 697224-75-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> e citrullimycin/cn 5

E1	1	CITRUCEL/CN
E2	1	CITRULLAMON V/CN
E3	0 -->	CITRULLIMYCIN/CN
E4	1	CITRULLIMYCINE A/CN
E5	1	CITRULLIMYCINE B/CN

=> s citrullimycine?/cn

L23 3 CITRULLIMYCINE?/CN

=> d 1-3 ide cbib abs

L23 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 406721-24-2 REGISTRY  
CN **Citrullimycine C (9CI)** (CA INDEX NAME)  
MF C42 H77 N3 O11  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL  
DT.CA Caplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Searched by: Mary Hale 571-272-2507 REM 1D86

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:278226 Citrullimycines, a process for their production and their use as pharmaceuticals. Hopmann, Cordula; Kurz, Michael; Broenstrup, Mark; Wink, Joachim (Aventis Pharma Deutschland G.m.b.H., Germany). Eur. Pat. Appl. EP 1193249 A1 20020403, 16 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (English). CODEN: EPXXDW. APPLICATION: EP 2000-121566 20001002.

AB The present invention relates to a compds. named citrullimycines which are obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309), and to their pharmaceutically acceptable salts. The present invention further relates to a process for the production of the citrullimycines, to the microorganism Streptomyces sp., ST 101396 (DSM 13309), to the use of the citrullimycines and their pharmaceutically acceptable salts as a pharmaceutical, in particular to their use as inhibitors of the neurotensin receptor, and to pharmaceutical compns. comprising Citrullimycines or a pharmaceutically acceptable salt thereof.

=> fil medl,hcap,biosis,embase,jicst,wpids;s citrullimycine? or l23

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.84	356.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.98	-5.45

FILE 'MEDLINE' ENTERED AT 10:11:53 ON 22 JUN 2004

FILE 'HCAPLUS' ENTERED AT 10:11:53 ON 22 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:11:53 ON 22 JUN 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 10:11:53 ON 22 JUN 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'JICST-EPLUS' ENTERED AT 10:11:53 ON 22 JUN 2004

COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'WPIDS' ENTERED AT 10:11:53 ON 22 JUN 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

L24	0 FILE MEDLINE
L25	1 FILE HCAPLUS
L26	0 FILE BIOSIS
L27	0 FILE EMBASE
L28	0 FILE JICST-EPLUS
L29	1 FILE WPIDS

TOTAL FOR ALL FILES

L30 2 CITRULLIMYCINE? OR L23

Searched by: Mary Hale 571-272-2507 REM 1D86

=> dup rem 130  
PROCESSING COMPLETED FOR L30  
L31 1 DUP REM L30 (1 DUPLICATE REMOVED)

=> d cbib abs


L31 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1  
2002:253013 Document No. 136:278226 **Citrullimycines**, a process for  
their production and their use as pharmaceuticals. Hopmann, Cordula;  
Kurz, Michael; Broenstrup, Mark; Wink, Joachim (Aventis Pharma Deutschland  
G.m.b.H., Germany). Eur. Pat. Appl. EP 1193249 A1 20020403, 16 pp.  
DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL,  
SE, MC, PT, IE, SI, LT, LV, FI, RO. (English). CODEN: EPXXDW.  
APPLICATION: EP 2000-121566 20001002.

AB The present invention relates to a compds. named **citrullimycines**  
which are obtainable by cultivation of Streptomyces sp. ST 101396 (DSM  
13309), and to their pharmaceutically acceptable salts. The present  
invention further relates to a process for the production of the  
**citrullimycines**, to the microorganism Streptomyces sp., ST 101396  
(DSM 13309), to the use of the **citrullimycines** and their  
pharmaceutically acceptable salts as a pharmaceutical, in particular to  
their use as inhibitors of the neurotensin receptor, and to pharmaceutical  
comps. comprising **Citrullimycines** or a pharmaceutically  
acceptable salt thereof.

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.88	368.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.69	-6.14

STN INTERNATIONAL LOGOFF AT 10:12:13 ON 22 JUN 2004





Creation date: 11-23-2004  
Indexing Officer: SMINGER - SYLVIA MINGER  
Team: 1600PrintWorkingFolder  
Dossier: 10056828

Legal Date: 11-24-2004

No.	Doccode	Number of pages
1	NOA	3
2	NOA	3
3	EXIN	2
4	892	3
5	1449	5
6	IIFW	1
7	FWCLM	1
8	SRFW	1

Total number of pages: 19

Remarks:

Order of re-scan issued on .....